|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 帕博利珠单抗治疗伴脑转移NSCLC患者的一项非随机、开放Ⅱ期试验的长期随访结果和生物标志物分析显示文摘背景与目的我们开展了一项帕博利珠单抗用于伴未治疗脑转移的非小细胞肺癌(non-small cell lung cancer,NSCLC)或黑色素瘤患者的疗效和安全性的II期试验,旨在评估程序性死亡受体1(programmed cell death 1,PD-1)抑制剂在中枢神经系统(central nervous system,CNS)中的疗效。中期结果已发表,现报道对NSCLC队列的更新分析结果。方法这是一项开放性、单中心、II期试验。纳入标准:年龄≥18岁,诊断为晚期NSCLC并伴有≥1个5 mm-20 mm脑转移病灶,既往从未治疗或之前放疗后进展,无神经系统症状,不需要激素治疗且美国东部肿瘤协作组(Eastern Cooperative Oncology Group,ECOG)<2分。患者每2周接受一次帕博利珠单抗(10 mg/kg)治疗。队列1为程序性死亡配体1(programmed cell death ligand 1,PD-L1)≥1%的患者,队列2为PD-L1<1%或未评估的患者。主要终点是脑转移患者缓解比例。所有经治患者均纳入疗效与安全性终点的分析。该研究已结束入组,并于Clinicaltrials.gov登记注册,注册号为NCT02085070。结果2014年3月31日-2018年5月21日,共42例患者接受治疗。中位随访时间为8.3个月(IQR:4.5个月-26.2个月)。队列1的37例患者中11例有脑转移缓解[29.7%(95%CI:15.9%-47.0%)]。队列2未观察到缓解。治疗相关的3级-4级不良事件(adverse events,AEs)包括2例肺炎、1例全身症状、1例结肠炎、1例肾上腺皮质功能不全、1例高血糖症和1例低钾血症。6例(14%)患者发生了治疗相关的严重不良事件,包括肺炎、急性肾损伤、低钾血症和肾上腺皮质功能不全。没有观察到治疗相关死亡病例。结论帕博利珠单抗治疗PD-L1≥1%的NSCLC伴脑转移患者有效,且对所有纳入的未经治疗的脑转移患者安全。需要进一步探索免疫治疗用于NSCLC合并CNS转移。 | Sarah B GOLDBERG Kurt A SCHALPER Scott N GETTINGER Amit MAHAJAN Roy S HERBST Anne C CHANG Rogerio LILENBAUM Frederick H WILSON Sacit Bulent OMAY James B YU Lucia JILAVEANU Thuy TRAN Kira PAVLIK Elin ROWEN Heather GERRSH Annette KOMLO Richa GUPTA Hailey WYATT Matthew RIBEIRO Yuval KLUGER Geyu ZHOU Wei WEI Veronica L CHANG Harriet M KLUGER 董晓荣(翻译/校对) | 2021 | 中国肺癌杂志2021，24，9： | 34 |
| 2 | Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: Epidemiological changes in Germany显示文摘AIM:To study the epidemiologic changes of gastroenteropancreatic neuroendocrine tumors(GEP-NET)in Germany,we analyzed two time periods 1976-1988 and1998-2006.METHODS:We evaluated epidemiological data of GEP-NET from the former East German National Cancer Registry(DDR Krebsregister,1976-1988)and its successor,the Joint Cancer Registry(GKR,1998-2006),which was founded after German reunification.Due to a particularly substantial database the epidemiological data from the federal states of Mecklenburg-Western Pomerania,Saxony,Brandenburg and Thuringia,covering a population of more than 10.8 million people,were analyzed.Survival probabilities were calculated using life table analysis.In addition,GEP-NET patients were evaluated for one or more second(non-GEP-NET)primary malignancies.RESULTS:A total of 2821 GEP neuroendocrine neoplasms were identified in the two registries.The overall incidence increased significantly between 1976 and2006 from 0.31(per 100.000 inhabitants per year)to2.27 for men and from 0.57 to 2.38 for women.In the later period studied(2004-2006),the small intestine was the most common site.Neuroendocrine(NE)neoplasms of the small intestine showed the largest absolute increase in incidence,while rectal NE neoplasms exhibited the greatest relative increase.Only the incidence of appendiceal NET in women showed little change between 1976 and 2006.Overall survival of patients varied for sex,tumor site and the two periods studied but improved significantly over time.Interestingly,about 20%of the GEP-NET patients developed one or more second malignancies.Their most common location was the gastrointestinal tract.GEP-NET patients without second malignancies fared better than those with one or more of them.CONCLUSION:The number of detected GEP-NET increased about 5-fold in Germany between 1976 and2006.At the same time,their anatomic distribution changed,and the survival of GEP-NET patients improved significantly.Second malignancies are common and influence the overall survival of GEP-NET patients.Thus,GEP-NET warrant our attention as well as intensive research on their tumorigenesis. | Hans Scherübl Brigitte Streller Roland Stabenow Hermann Herbst Michael Hopfner Christoph Schwertner Joachim Steinberg Jan Eick Wanda Ring Krishna Tiwari Soren M Zappe | 2013 | World Journal of Gastroenterology2013，19，47： | 16 |
| 3 | Budd-Chiari syndrome:A single-center experience显示文摘AIM:To investigate challenges,risk factors,prognostic indicators,and treatment outcomes associated with Budd-Chiari syndrome(BCS)at a tertiary care center.METHODS:A retrospective cohort study was conducted at the University of Pennsylvania in patients with a diagnosis of BCS or hepatic vein thrombosis.All patients receiving care at the University of Pennsylvania,and who had at least 2 clinical encounters in the University of Pennsylvania Health system from January1,2008 to September 10,2013 were eligible for study inclusion.Data were extracted from the electronic medical record of each patient,and recorded in a secure Research Electronic Data Capture database.Logistic regression analyses were applied to identify predictors of outcome of liver transplant(LT)or death.RESULTS:Between January 1,2008 and September10,2013,forty-seven patients were identified.Median age was 42.4 years.Thirty-one(66.0%)were women.A majority were Caucasian(68.1%).At diagnosis,43(91.5%)patients had ascites,27(57.4%)patients had a hematologic disorder associated with a hypercoagulable state and 26(55.3%)had cirrhosis.Forty(85.1%)patients were on anticoagulation(AC),30(63.8%)of whom were maintained on warfarin.Two patients(4.3%)underwent thrombolytic therapy.A transjugular intrahepatic portosystemic shunt(TIPS)was placed in21(44.7%)patients,19(90.5%)of whom were also on AC.Twenty-one(44.7%)received AC alone.Over a median of 974 d,8(17.0%)patients received LT,and10(21.3%)died.The median time from listing to death was 26 mo[interquartile range(IQR)=16,65)].TIPS with AC was utilized more frequently in younger patients(P=0.02).Age,cirrhosis and chronic kidney disease(CKD)were significant predictors of LT or death.CONCLUSION:AC alone was employed as frequently as TIPS with AC,though the latter was used more frequently in younger patients with polycythemia vera.There were no significant differences in treatment outcome regardless of the therapeutic intervention employed.Significant predictors of poor prognosis included age,cirrhosis and CKD. | Tanya M Pavri Alan Herbst Rajender Reddy Kimberly A Forde | 2014 | World Journal of Gastroenterology2014，20，43： | 2 |
| 4 | Work- flow mining A survey of issues and approaehes显示文摘 | van der Aalst W M P van Dongen B F Herbst J | 2003 | Data and Know ledge Engineering2003，47，2： | 1 |
| 5 | Increases in adult life expectancy in rural South Africa:valuing the scale-up of HIV treatment显示文摘 | Bor J Herbst A J Newell M L | 2013 | Science2013，339，6122： | 1 |
| 6 | Collagen type X Ⅷ/endostatin is differentially expressed in primary and metastatic colorectal cancers and ovarian carcinomas 显示文摘 | Guenther U Herbst H Bauer M | 2001 | Br J Cancer2001，85，10： | 1 |
| 7 | The reaction of nitriles with hydrazoic acid : synthesis of monosubstituted tetrazoles 显示文摘 | MIHINA JS HERBST R M | 1950 | J Org Chem1950，15，： | 1 |
| 8 | RGB-D mapping: Using Kinect-style depth cameras for dense 3D modeling of indoor environments显示文摘 | Henry P Krainin M Herbst E | 2012 | International Journal of Robotics Research2012，31，5： | 1 |
| 9 | RGB-D mapping: Using Kinect-style depth cameras for dense 3D modeling of indoor environments显示文摘 | Henry P Krainin M Herbst E | 2012 | International Journal of Robotics Research2012，31，5： | 1 |
| 10 | Local recurrence of colorectal cancer:effect of early detection and aggressive surgery显示文摘 | Schiessel R Wunderlich m Herbst F | 1986 | Br J Surg1986，75，5： | 1 |
| 11 | Absence of HHV-8 DNA in hobnail hemangiomas显示文摘 | Gutzmer R Kaspari M Herbst R A | 2002 | J Cutan Pathol2002，29，3： | 1 |
| 12 | Eclampsia in Scandinavia:Incidence,substandard care,and potentially preventable cases显示文摘 | Andersgaard A B Herbst A Johansen M | 2006 | Acta Obstet Gynecol Scand2006，85，8： | 1 |
| 13 | Efficacy of gefitinib,an inhibitor of the epidermal growth factor receptor tyrosine kinase,in symptomatic patients with non-small cell lung cancer:a randomized trial显示文摘 | Kris M Natale R Herbst R | 2003 | JAMA2003，290，： | 1 |
| 14 | On the extension of the Painleve property to difference equations显示文摘 | ABLOWITZ M J HALBURD R HERBST B | 2000 | Nonlin- earity2000，13，3： | 1 |
| 15 | Absence of anaplastic lymphoma kinase (ALK) and Epstein-Barr virus gene products in primary cutaneous anaplastic large cell lymphoma and lymphomatoid papulosis显示文摘 | Sander C Tronnier M | 1997 | Br J Dermatol1997，137，5： | 1 |
| 16 | Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well- tolerated and has activity in non-small- cell lung cancer and other solid tumors:results of a phase I trial 显示文摘 | Herbst R S Maddox A M Rothenberg M L | 2002 | J Clin Oncol2002，20，18： | 1 |
| 17 | Comparative study of root- canal preparation using Lightspeed and Quantec SC rotary NiTi instruments显示文摘 | Htilsmann M Herbst U Schafers F | 2003 | Int Endod J2003，36，11： | 1 |
| 18 | Demiatologic side effects associated with gefitinib therapy:clmical experience and management显示文摘 | Herbst RS Lorusso PM Purdom M | 2003 | Clin Lung Cancer2003，4，6： | 1 |
| 19 | Meas-uring and Modeling the Rainfall Interception Loss by Hedg-erows in Southern England显示文摘 | HERBST M ROBERTS J M ROSIER P T W | 2006 | Agricultural and Forest Me-teorology2006，141，： | 1 |
| 20 | Selective oralepidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well -tolerated and has activity in non -small -cell lung cancer and other solid tumors:results of a phase I trial 显示文摘 | Herbst R S Maddox A M Rothenberg M L | 2002 | J Clin Oncol2002，20，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员